Long-term Follow-Up of a Phase 1 Study of Arlocabtagene Autoleucel (arlo-cel; BMS-986393) in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM)Susan Bal, Jesús G. Berdeja, Myo Htut et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior RegimensSusan Bal, Omar Nadeem, Adriana Rossi et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0